FDA approves Protalix's (PLX) Gaucher Disease drug Elelyso
The FDA approved Protalix's (NYSE: PLX) Gaucher Disease drug Elelyso
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease
- Cempra (CEMP): Two Key Upcoming Catalysts - Needham
- Ultragenyx Pharma (RARE) Commences KRN23 Phase 3 in XLH
Create E-mail Alert Related CategoriesFDA, Hot FDA News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!